Access cutting-edge atopic dermatitis treatment through this phase 3 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Birmingham location
Preparing your pre-screening questions…
Access atopic dermatitis specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related atopic dermatitis treatment provided free
Check if you qualify for this atopic dermatitis clinical trial in Birmingham, AL
No-Cost Study Care
Local to Birmingham
Convenient for AL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated. * This study is seeking participants who: Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20. Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.
Sponsor: Pfizer
Yes, this clinical trial (NCT07765888) has an active research site in Birmingham, AL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for atopic dermatitis treatment options in Birmingham, AL, this clinical trial (NCT07765888) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all atopic dermatitis clinical trials near you to find additional studies recruiting in your area.
See all atopic dermatitis clinical trials recruiting in Birmingham — not just this study.
Browse Atopic Dermatitis Trials in Birmingham →